Abstract: . . .  1993;39(2):65-72. 13. Echanove Errazti I, Velasco Rami JA, Ridocci Soriano F, Pomar Domingo F, Vilar Herrero V, Martinez Alzamora N. Changes in hospital mortality from acute myocardial infarction during the last 15 years. The impact of reperfusion treatments. Rev Esp Cardiol. 1999;52(8):547-55. 14. Schei MA, Hessen JO, Kildahl-Andersen O. Thrombolytic therapy in acute myocardial infarctions. Tidsskr Nor Laegeforen. 1998;118(5):692-5. 15. Reikvam A. Use of thrombolytic agents and other drugs in acute myocardial infarction. Tidsskr Nor Laegeforen. 1996;116(14):1671-4. 16. Eagle K, Goodman S, Avezum A, Budaj A, Sullivan C, Lpez-Sendn J. Practice variation and Page 9 Causas de la no-tromblisis en el infarto agudo del miocardio y beneficios de su uso missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet. 2002;359:373-7. 17. French JK, Williams BF, Hart HH, Wyatt S, Poole JE, Ingram C, et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. Br Med J. 1996 29;312 (7047):1637-41. 18. Ochoa Gomez FJ, Carpintero Escudero JM, Ramalle-Gomara E, Lisa Caton V, Marco Aguilar P. Exclusion causes to thrombolytic treatment in myocardial infarction. Ann Med Interne. 1998;15 (2):80-2. 19. Mahon NG, O'rorke C, Codd MB, . . .
. . .  Errazti I, Velasco Rami JA, Ridocci Soriano F, Pomar Domingo F, Vilar Herrero V, Martinez Alzamora N. Changes in hospital mortality from acute myocardial infarction during the last 15 years. The impact of reperfusion treatments. Rev Esp Cardiol. 1999;52(8):547-55. 14. Schei MA, Hessen JO, Kildahl-Andersen O. Thrombolytic therapy in acute myocardial infarctions. Tidsskr Nor Laegeforen. 1998;118(5):692-5. 15. Reikvam A. Use of thrombolytic agents and other drugs in acute myocardial infarction. Tidsskr Nor Laegeforen. 1996;116(14):1671-4. 16. Eagle K, Goodman S, Avezum A, Budaj A, Sullivan C, Lpez-Sendn J. Practice variation and Page 9 Causas de la no-tromblisis en el infarto agudo del miocardio y beneficios de su uso missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet. 2002;359:373-7. 17. French JK, Williams BF, Hart HH, Wyatt S, Poole JE, Ingram C, et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. Br Med J. 1996 29;312 (7047):1637-41. 18. Ochoa Gomez FJ, Carpintero Escudero JM, Ramalle-Gomara E, Lisa Caton V, Marco Aguilar P. Exclusion causes to thrombolytic treatment in myocardial infarction. Ann Med Interne. 1998;15 (2):80-2. 19. Mahon NG, O'rorke C, Codd MB, McCann HA, McGarry K, Sugrue DD. Hospital . . .
--3000,2,750,3176,22003